Collaborations

Home > About Us > Collaborations

About Us

Strategic collaborations provide expanded opportunities to apply PTC's scientific approach to additional therapeutic areas, access to development and commercialization capabilities and significant financial resources.

PTC strategic alliances to date include:

 

AstraZeneca - Exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases.



Celgene Corporation - A $20 million equity investment. In addition, Celgene exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMS™ (Gene Expression Modulation by Small-molecules) technology.

 


Cystic Fibrosis Foundation — A grant for up to $25 million in support of key Phase 2b clinical trials for ataluren (PTC124™) in nonsense mutation cystic fibrosis.


Genzyme Corporation— PTC has worldwide rights for the development and commercialization of ataluren but Genzyme has an option to commercialize ataluren outside the U.S. and Canada in indications other than nonsense mutation Duchenne/Becker muscular dystrophy.


Gilead — Exclusive research collaboration and licensing arrangement for the development of orally bioavailable small molecules through the application of PTC's proprietary GEMS (Gene Expression Modulation by Small-molecules) technology.


Muscular Dystrophy Association (MDA)—
Two grants totaling $2.5 million to support the development of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy.


Merck & Co., Inc. (Schering-Plough Corporation) — $200 million collaboration for the development and commercialization of the compounds in the hepatitis C program.


Parent Project Muscular Dystrophy (PPMD) — Support for preclinical development of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) and a collaboration to discover new drugs to treat DMD called Project Catalyst.



Pfizer Inc. - An exclusive research collaboration and licensing agreement for the development of pharmaceuticals through the application of PTC’s GEMS™ (Gene Expression Modulation by Small-molecules) technology.


Roche - An exclusive research collaboration and licensing agreement for the development of orally bioavailable small molecules utilizing PTC's technology called Gene Expression Modulation by Small-molecules (GEMS™). The collaboration focuses initially on four CNS disease targets to be jointly selected.


Spinal Muscular Atrophy Foundation — $13 million in grant funding to support discovery of new treatments for spinal muscular atrophy.



Wellcome Trust - $5.4 million Seeding Drug Discovery Award to support the development of drugs that target BMI1, a protein that has been linked to drug resistant cancers.